Skip to main content

Table 1 Comparison between infliximab and non-infliximab

From: Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure—a cautionary case series

  Infliximab (n = 7) Non-infliximab (n = 17)
Age (years) 60 (47–66) 66 (42–91)
Sex (m/w) 6/1 11/7
BMI (kg/m2) 32.4 (24.0–36.1) 28.7 (22–45)
ICU admission (n) 6 (86%) 15 (88%)
Death related to COVID-19 1 (14.2%) 6 (35.3%)
Mechanical ventilation (n) 3 (42.8%) 9 (52.9%)
ECMO (n) 2 (28.6%) 1 (5.9%)
RR syst (mmHg) 110 (100–125) 128 (94–174)
AF (1/min) 24 (18–39) 27 (16–42)
HF (1/min) 72 (61–120) 84 (60–127)
SpO2 (%) 91 (89–96) 92 (84–99)
Temperature (°C) 37.7 (36.2–37.7) 37.1 (36.7–39.4)
WBC (Gpt/l) 8.9 (3.4–16.4) 7.0 (2.2–13)
CRP (mg/l) 178.1 (113.4–401.3) 187 (18.7–323)
PCT (ng/ml) 0.28 (0.06–15.99) 0.58 (0.1–11)
Ferritin (μg/l) 2777.4 (697–70,693.8) 1453.0 (124.7–7391)
d-dimer (μg/l) 683 (10.2–48,588) 475.5 (146–8015)
LDH 10.6 (8.23–131.65) 6.54 (3.31–11.8)
Creatinine (mmol/l) 92.0 (59–303) 77.5 (55–384)a
ALAT (μmol/l*s) 2.79 (0.62–3.19) 0.55 (0.1–2.93)
  1. Data are presented as absolute number and percentage or as median and range
  2. aExcluding patients with chronic hemodialysis